Singapore startup Mesh Bio secures $3.5M to democratize digital twin technology.

TLDR: Singapore-based startup Mesh Bio has raised $3.5 million in series A financing to make its digital twin technologies available at scale. The funding will allow the company to offer its solutions to healthcare providers in Hong Kong and Southeast Asia, with a focus on Indonesia and the Philippines. Mesh Bio’s digital twin technologies use predictive analytics to transform chronic disease management. The company recently received regulatory approval for its HealthVector Diabetes software medical device in Singapore and is currently conducting an implementation pilot in several hospitals for potential clinical adoption.

Singapore-based startup Mesh Bio has raised $3.5 million in series A financing to make its digital twin technologies available at scale. The funding will allow the company to offer its solutions to healthcare providers in Hong Kong and Southeast Asia, with a focus on Indonesia and the Philippines. Mesh Bio’s digital twin technologies use predictive analytics to transform chronic disease management.

The company recently received regulatory approval for its HealthVector Diabetes software medical device in Singapore, and it is currently being piloted in several hospitals for potential clinical adoption. The platform enables data-driven care delivery and has been used by more than 120 medical centers across Singapore, Malaysia, and Indonesia for preventive health screening.

The funding round was led by East Ventures, a venture capital firm focusing on Southeast Asia, and also saw participation from Elev8, Seed Capitals, and other existing shareholders.

Key Takeaways:

• Singapore-based startup Mesh Bio has raised $3.5 million in series A financing to make its digital twin technologies available at scale.
• The funding will allow the company to offer its solutions to healthcare providers in Hong Kong and Southeast Asia, with a focus on Indonesia and the Philippines.
• Mesh Bio’s digital twin technologies use predictive analytics to transform chronic disease management.
• The company recently received regulatory approval for its HealthVector Diabetes software medical device in Singapore.
• The platform enables data-driven care delivery and has been used by more than 120 medical centers across Singapore, Malaysia, and Indonesia for preventive health screening.